Closure of atrial septal defect and patent foramen ovale
Closing an atrial septal defect or a patent foramen ovale means shutting the opening between the two upper chambers of the heart, with a catheter-delivered implant or by surgery. MeSH describes a septal occluder device as a catheter-delivered implant used for closing abnormal holes in the cardiovascular system, especially heart septal defects. A 2023 open-access review says transcatheter device closure is the preferred way of closing septum secundum defects and that careful patient selection and follow-up are necessary. A 2026 review says the indications, timing and long-term safety of patent foramen ovale closure remain controversial.
Also called PFO closure · ASD closure · Septal closure
- Intervention
- In this atlas
Overview
Technical summary
MeSH descriptor D055989, Septal Occluder Device (broad, because the descriptor names the implant and not the procedure). Its scope note describes a catheter-delivered implant used for closing abnormal holes in the cardiovascular system, especially heart septal defects. MedlinePlus lists cardiac catheterization to repair simple defects, such as a small hole in the inside wall of the heart, among the treatments for congenital heart defects. A 2023 open-access narrative review of closure devices for atrial septal defect (Cureus, CC BY 3.0) says transcatheter device closure is the preferred way of closing septum secundum defects; that a meta-analysis found the transcatheter approach had a high success rate and lower rates of adverse events and shorter hospital stays than surgery; and that complications are relatively rare. A 2026 open-access review of patent foramen ovale (MedComm, CC BY 4.0) says transcatheter closure has evolved into a secondary prevention strategy for patients with a PFO-related stroke, that apart from three randomized trials in stroke secondary prevention no other randomized trial has yielded encouraging results, and that long-term surveillance for arrhythmias and residual shunts is still needed. These are the reviews' statements; the atlas gives no rule about who should have an opening closed, by which route, or what medicine follows, and records no trial figures. The US approval of one device for secundum atrial septal defect is on that product's own page.
About this intervention
- Type
- Procedure
- Mechanism
- A catheter-delivered implant, carried by a thin tube guided through a vein into the heart, closes the opening (MeSH scope note; MedlinePlus).
Classification codes
-
D055989
Claims and evidence
Context People having a patent foramen ovale closed (2026 review)
- Recipient
- Recipient not specified
- Population
- People with a patent foramen ovale whose closure is considered, mainly after a PFO-related stroke, as the review describes them.
- Care setting
- Not stated for the review as a whole. The review discusses the closure procedure and its follow-up.
- Geography
- Not stated for the review as a whole.
- Life stage
- Not restricted. The review lists elderly people, children, pregnant women and athletes as groups in whom diagnostic and predictive tools need further investigation; this record makes no statement about them.
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (a narrative review; follow-up periods of individual studies are not recorded).
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Having a patent foramen ovale
- Being considered for closure of a patent foramen ovale
- Excluded
- None stated
A 2026 open-access review of patent foramen ovale (MedComm) says transcatheter closure has evolved into a secondary prevention strategy for patients with a PFO-related stroke, and that substantial evidence has established transcatheter closure for secondary prevention in patients with cryptogenic stroke. It says the indications, timing and long-term safety of closure remain controversial, that long-term surveillance for complications such as arrhythmias and residual shunts is still needed, and that apart from three randomized trials in stroke secondary prevention no other randomized trial has yielded encouraging results for closure.
Applies to Recipient not specified People having a patent foramen ovale closed (2026 review)
- Certainty method
- Not assessed
- Limitations
- A narrative review; the statements come from its abstract, introduction and conclusions, which cite the trials without giving figures here. The review uses the abbreviation CS for cryptogenic stroke. Trial figures, device types and patient-selection criteria are not repeated, and the atlas states no rule about who should have a patent foramen ovale closed.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (5)
-
- Locator
- Introduction, para 2, sentence 4 (part)
- How it applies
- Transcatheter closure has evolved into a secondary prevention strategy for PFO-related stroke.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Conclusions and Perspectives, para 1, sentence 3
- How it applies
- Substantial evidence has established closure for secondary prevention in cryptogenic stroke.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, para 1, sentence 3 (end)
- How it applies
- Indications, timing and long-term safety remain controversial.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Conclusions and Perspectives, para 2, sentence 4 (end)
- How it applies
- Long-term surveillance for complications such as arrhythmias and residual shunts is still needed.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Conclusions and Perspectives, para 3, sentence 1
- How it applies
- Apart from three trials in stroke secondary prevention, no other randomized trial has yielded encouraging results.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
f0b4ebb513263ec28c3efbbd9df9af28be224756753838bc1b172e0e6fb2a096- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/, content-type ccbylicense, CC BY 4.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
Context People having an atrial septal defect closed (2023 device review)
- Recipient
- Recipient not specified
- Population
- People whose atrial septal defect is closed through a catheter, as the review describes them. It also covers some patients with a patent foramen ovale, and the comparison with surgery.
- Care setting
- Catheterization laboratory, as the review describes the procedure. Surgery is mentioned only as a comparison.
- Geography
- The review discusses United States device approvals; this record does not use them.
- Life stage
- Not restricted in the abstract or introduction. The review includes studies of adults and of children; this record makes no statement about newborns, pregnancy or any age group.
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (a narrative review; follow-up periods of individual studies are not recorded).
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Having an atrial septal defect that is closed through a catheter
- Excluded
- None stated
A 2023 open-access narrative review of devices for transcatheter closure of atrial septal defect (Cureus) says transcatheter device closure is the preferred way of closing septum secundum defects. It says a meta-analysis found the transcatheter approach had a high success rate, lower rates of adverse events and shorter hospital stays compared with surgery, that complications have been reported but are relatively rare, and that careful patient selection and follow-up are necessary to minimize complications and ensure optimal outcomes. MedlinePlus lists cardiac catheterization to repair simple defects, such as a small hole in the inside wall of the heart, among the treatments for congenital heart defects.
Applies to Recipient not specified People having an atrial septal defect closed (2023 device review)
- Certainty method
- Not assessed
- Limitations
- A narrative review of devices, written in 2023; the outcome statements come from studies it cites, and its device list and trial figures are not repeated. The review mentions surgical closure only in comparison. The atlas states no rule about who should have a defect closed or by which route; the MedlinePlus sentence is general patient information.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (8)
-
Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices
- Locator
- Introduction and background, para 1, sentence 9 (first part)
- How it applies
- Transcatheter device closure is the preferred way to close septum secundum defects.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices
- Locator
- Abstract, para 1, sentence 15 (first part)
- How it applies
- A meta-analysis found the transcatheter approach had a high success rate.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices
- Locator
- Abstract, para 1, sentence 15 (end)
- How it applies
- Lower rates of adverse events and shorter hospital stays than surgery.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices
- Locator
- Abstract, para 1, sentence 16 (first part)
- How it applies
- Complications of transcatheter closure have been reported.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices
- Locator
- Abstract, para 1, sentence 17
- How it applies
- Complications are relatively rare.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Transcatheter Closure of Atrial Septal Defect: A Review of Currently Used Devices
- Locator
- Abstract, para 1, sentence 20
- How it applies
- Careful patient selection and follow-up are necessary.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
53c591583671de4cfe5e457b41f5d738ca323fdfed42568cf7b0c1dd76feec64- Reuse basis
- PMC Open Access subset article under the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/3.0/, content-type ccbylicense, CC BY 3.0). The article's own license element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
Supports Congenital Heart Defects (MedlinePlus health topic)
- Locator
- Summary, What are the treatments for congenital heart defects?
- How it applies
- MedlinePlus: cardiac catheterization to repair simple defects.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
8a8235db9024c57a4d94c6eca43f79959079f4a59cadc7bbe15b9e7e583f480d- Reuse basis
- MedlinePlus says works produced by the federal government are not copyrighted and that its summaries on health topic pages are in the public domain, and asks users to acknowledge MedlinePlus as the source (MedlinePlus using-content page, fetched 2026-10-14, hash only). Some images on MedlinePlus are copyrighted; this atlas uses none. The raw page is committed in the atlas repository. Terms re-checked on 2026-11-08 at https://medlineplus.gov/about/using/usingcontent/ (page not committed; sha256 0825c88f5bd1dade7c8693bad8035b0d1f25fd0b8c5053e488c618fb2b62e722). That page says health topic page summaries, medical test information and Genetics page summaries are in the public domain, and that A.D.A.M. Medical Encyclopedia content (medlineplus.gov/ency/), ASHP drug monographs and most images are copyrighted. This source is a public-domain page, not an A.D.A.M. page, so public text stays quote; any A.D.A.M. page would be cite_only.
-
Background MeSH scope note for descriptor D055989 (Septal Occluder Device)
- Locator
- scopeNote.@value, sentence 1 (first part)
- How it applies
- MeSH scope note for a septal occluder device.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
0bf9f56e8a4655464b7574c149341ac7e89f41d00cf0fa2f804e89c01d274f37- Reuse basis
- The NLM web policies page (sha256 c8b7026b5c3fcfd1b0cb88755077f6a99a5f2159eecd42b0e7d1a5ad9b30ec55, hash only) says works produced by the U.S. government are not subject to copyright protection in the United States and asks users to acknowledge NLM as the source. The NLM MeSH terms and conditions page (sha256 f33b14141a5b6c8a2b1464c751dbdbb0a0d476c913851bf2a8c3d5c14b1afce7, hash only) asks redistributors to maintain current data or to make known that their copy may not reflect the most current data. This copy was fetched on 2026-11-18 and may not reflect the most current data. The raw bytes are committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact A 2023 review says transcatheter device closure is the preferred way to close septum secundum defects; its outcome statements come from studies it cites: Atrial septal defect
Applies to Recipient not specified People having an atrial septal defect closed (2023 device review)
A 2023 open-access narrative review of devices for transcatheter closure of atrial septal defect (Cureus) says transcatheter device closure is the preferred way of closing septum secundum defects. It says a meta-analysis found the transcatheter approach had a high success rate, lower rates of adverse events and shorter hospital stays compared with surgery, that complications have been reported but are relatively rare, and that careful patient selection and follow-up are necessary to minimize complications and ensure optimal outcomes. MedlinePlus lists cardiac catheterization to repair simple defects, such as a small hole in the inside wall of the heart, among the treatments for congenital heart defects.Limitations. A narrative review of devices, written in 2023; the outcome statements come from studies it cites, and its device list and trial figures are not repeated. The review mentions surgical closure only in comparison. The atlas states no rule about who should have a defect closed or by which route; the MedlinePlus sentence is general patient information.
-
Claim, not a settled fact A 2026 review says closure is a secondary prevention strategy for PFO-related stroke, and that indications, timing and long-term safety remain controversial: Patent foramen ovale
Applies to Recipient not specified People having a patent foramen ovale closed (2026 review)
A 2026 open-access review of patent foramen ovale (MedComm) says transcatheter closure has evolved into a secondary prevention strategy for patients with a PFO-related stroke, and that substantial evidence has established transcatheter closure for secondary prevention in patients with cryptogenic stroke. It says the indications, timing and long-term safety of closure remain controversial, that long-term surveillance for complications such as arrhythmias and residual shunts is still needed, and that apart from three randomized trials in stroke secondary prevention no other randomized trial has yielded encouraging results for closure.Limitations. A narrative review; the statements come from its abstract, introduction and conclusions, which cite the trials without giving figures here. The review uses the abbreviation CS for cryptogenic stroke. Trial figures, device types and patient-selection criteria are not repeated, and the atlas states no rule about who should have a patent foramen ovale closed.
Record details
- Record id
cardio:closure-of-pfo-and-asd- Content hash
0282e2149425c7be527744bb38787576a955e48f5c47edfc636b21264b6dd37e